Biogen Inc. (BIIB)
| Market Cap | 29.34B |
| Revenue (ttm) | 9.67B |
| Net Income (ttm) | 1.16B |
| Shares Out | 145.66M |
| EPS (ttm) | 7.94 |
| PE Ratio | 25.37 |
| Forward PE | 12.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 991,157 |
| Open | 200.57 |
| Previous Close | 197.59 |
| Day's Range | 200.11 - 204.18 |
| 52-Week Range | 189.44 - 269.43 |
| Beta | -0.06 |
| Analysts | Buy |
| Price Target | 278.13 (+38.07%) |
| Earnings Date | Nov 6, 2024 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab bio... [Read more]
Financial Performance
In 2023, Biogen's revenue was $9.84 billion, a decrease of -3.32% compared to the previous year's $10.17 billion. Earnings were $1.16 billion, a decrease of -61.89%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is $278.13, which is an increase of 38.07% from the latest price.
News
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™
INCHEON, South Korea and CAMBRIDGE, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency's (EMA) Commit...
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB) Cantor Fitzgerald Global Healthcare Conference Call September 18, 2024 1:20 PM ET Company Participants Chuck Triano - Head, Investor Relations Conference Call Participants E...
US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
Despite favorable views on litifilimab, AbbVie's Rinvoq and BMS' Sotyktu capture the most prescriber interest for approval, according to Spherix Global Insights. Despite favorable views on litifilimab...
Healthcare Stocks Have Popped. Consider These 2 That Haven't.
Money has poured into the sector as markets have grown concerned about the economy.
Biogen Board Appoints Two New Independent Directors
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development Dr. Lloyd Minor and Prof Sir Menelas Pangalos brin...
Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE™ (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy
Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800) Phase 3 clinical data in totality ...
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to tre...
Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript
Biogen Inc. (NASDAQ:BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Executi...
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the saf...
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive f...
Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is gene...
OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ
DAVIS, Calif.--(BUSINESS WIRE)--The non-profit consortium is developing publicly accessible advanced AI-based drug discovery software tools.
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
Biogen Inc.'s stock BIIB rose 1.8% in premarket trading on Thursday after the drug aker boosted its outlook for its adjusted 2024 profit and topped Wall Street's second-quarter profit expectations. Th...
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
Biogen reported second-quarter earnings and revenye that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, Leqem...
Biogen lifts 2024 profit forecast on hopes of new product launches
Biogen lifted its full-year earnings forecast on Thursday, as the launch of new treatments such as rare disease drug Skyclarys is expected to make up for a market-share loss of its older multiple scle...
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PI...
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data prese...
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 2024
51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease
CAMBRIDGE, Mass. & BREA, Calif. & TOKYO--(BUSINESS WIRE)-- #CDMO--Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-ba...
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The Eu...
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eisai and Biogen's breakthrough treatment for early Alzheimer's disease, in a blow to the drugmakers as take-up in the U.S. has been slower than...
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
Sage Therapeutics Inc. SAGE and Biogen Inc. BIIB announced results Wednesday from the Phase 2 KINETIC 2 dose-range study of SAGE-324 (BIIB124) as a potential treatment for essential tremor (ET).
Sage Therapeutics' stock dives as failed trial hits Biogen collaboration
Companies halt development of neurological treatment, putting new pressure on Biogen's pipeline, analysts say.